Takeru Funakoshi

Prof. Takeru Funakoshi

Keio University School of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KKKoji Kurose
Koji Kurose
YOYoshihiro Ohue
Yoshihiro Ohue
HWHisashi Wada
Hisashi Wada
SIShinsuke Iida
Shinsuke Iida
TITakashi Ishida
Takashi Ishida
ENEiichi Nakayama
Eiichi Nakayama
Purpose: FoxP3+ Tregs inhibit immune responses against tumors. KW-0761 is a humanized anti-human CCR4 monoclonal antibody (mAb) that has antibody-dependent cellular cytotoxicity activity. Depletion of CCR4-expressing FoxP3+ CD4 Tregs by KW-0761 infusion was investigated in solid cancer patients. Experimental Design: We conducted a phase Ia clinical trial of KW-0761 infusion in 7 lung and 3 esophageal cancer patients. Toxicity, clinical efficacy, changes in lymphocyte subpopulations, including Tregs, and induction of immune responses were analyzed. Results: The results showed that KW-0761 infusion in a dose range between 0.1 mg/kg and 1.0 mg/kg was safe and well tolerated. No dose-limiting toxicity was observed. Four of 10 patients showed stable disease during treatment and were long survivors. The monitoring of FoxP3+ Tregs in the peripheral blood mononuclear cells during treatment indicated efficient depletion of those cells, even at the lowest dose of 0.1 mg/kg used. The reduction in Th 1 CD4 T cells and CD8 T cells was limited, whereas a significant reduction was observed with Th 2 and Th 17 CD4 T cells. Immune responses to cancer/testis (CT) antigens and an autoantibody response to thyroid peroxidase were observed in some patients. Conclusions: The findings showed Tregs depletion and the possible occurrence of an immune response following KW-0761 infusion. Combined use of KW-0761 to deplete FoxP3+ Tregs with other immunotherapies, such as cancer vaccines or checkpoint inhibitors, is a promising approach to augment immune responses. Clin Cancer Res; 21(19); 4327–36. ©2015 AACR.

15 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YNYoshio Nakamura
Yoshio Nakamura
SKShigehisa Kitano
Shigehisa Kitano
ATAkira Takahashi
Akira Takahashi
ATArata Tsutsumida
Arata Tsutsumida
KNKenjiro Namikawa
Kenjiro Namikawa
NYNaoya Yamazaki
Naoya Yamazaki
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

1 November 2017 in Journal of Dermatological Science
Verified
Journal Article
Closed access
YFYasuhiro Fujisawa
Yasuhiro Fujisawa
KYKoji Yoshino
Koji Yoshino
AOAtsushi Otsuka
Atsushi Otsuka
TFTakeru Funakoshi
Takeru Funakoshi
TFTaku Fujimura
Taku Fujimura
SMShigeto Matsushita
Shigeto Matsushita

16 February 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KFKeitaro Fukuda
Keitaro Fukuda
TFTakeru Funakoshi
Takeru Funakoshi
Extramammary Paget’s disease (EMPD) is a rare, slow-growing, cutaneous adenocarcinoma that usually originates in the anogenital area and axillae outside the mammary glands. EMPD mostly progresses slowly and is often diagnosed as carcinoma in situ; however, upon becoming invasive, it promptly and frequently metastasizes to regional lymph nodes, leading to subsequent distant metastasis. To date, several chemotherapy regimens have been used to treat metastatic EMPD; however, they present limited effect and patients with distant metastasis exhibit a poor prognosis. Recently, basic and translational investigative research has elucidated factors and molecular mechanisms underlying the promotion of metastasis, which can lead to targeted therapy-based emerging treatment strategies. Here, we aim to discuss current therapies and their limitations; advancements in illustrating mechanisms promoting invasion, migration, and proliferation of EMPD tumor cells; and future therapeutic approaches for metastatic EMPD that may enhance clinical outcomes.

29 July 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KFKeitaro Fukuda
Keitaro Fukuda
KOKen Okamura
Ken Okamura
RRRebecca L. Riding
Rebecca L. Riding
XFXueli Fan
Xueli Fan
KAKhashayar Afshari
Khashayar Afshari
JHJohn E. Harris
John E. Harris
The STING and absent in melanoma 2 (AIM2) pathways are activated by the presence of cytosolic DNA, and STING agonists enhance immunotherapeutic responses. Here, we show that dendritic cell (DC) expression of AIM2 within human melanoma correlates with poor prognosis and, in contrast to STING, AIM2 exerts an immunosuppressive effect within the melanoma microenvironment. Vaccination with AIM2-deficient DCs improves the efficacy of both adoptive T cell therapy and anti–PD-1 immunotherapy for “cold tumors,” which exhibit poor therapeutic responses. This effect did not depend on prolonged survival of vaccinated DCs, but on tumor-derived DNA that activates STING-dependent type I IFN secretion and subsequent production of CXCL10 to recruit CD8+ T cells. Additionally, loss of AIM2-dependent IL-1β and IL-18 processing enhanced the treatment response further by limiting the recruitment of regulatory T cells. Finally, AIM2 siRNA-treated mouse DCs in vivo and human DCs in vitro enhanced similar anti-tumor immune responses. Thus, targeting AIM2 in tumor-infiltrating DCs is a promising new treatment strategy for melanoma.

18 February 2016 in OncoImmunology
Verified
Journal Article
Open access
YHYuki Honda
Yuki Honda
AOAtsushi Otsuka
Atsushi Otsuka
SOSachiko Ono
Sachiko Ono
YYYosuke Yamamoto
Yosuke Yamamoto
JSJudith A. Seidel
Judith A. Seidel
KKKenji Kabashima
Kenji Kabashima
Cutaneous angiosarcoma (CAS) is a malignant sarcoma with poor prognosis. Programmed cell death-1 (PD-1)/programmed cell death-1 ligand-1 (PD-L1) expression reflects antitumor immunity, and is associated with patient prognosis in various cancers. The purpose of this study is to investigate the relationship between PD-1/PD-L1 expression and CAS prognosis. CAS cases (n = 106) were immunohistochemically studied for PD-L1 and PD-1 expression, and the correlation with patient prognosis was analyzed. PD-L1 expression was assessed by flow cytometry on three CAS cell lines with or without IFNγ stimulation. A total of 30.2% of patients' samples were positive for PD-L1, and 17.9% showed a high infiltration of PD-1-positive cells. Univariate analysis showed a significant relationship between a high infiltration of PD-1-positive cells with tumor site PD-L1 expression and favorable survival in stage 1 patients (p = 0.014, log-rank test). Multivariable Cox-proportional hazard regression analysis also showed that patients with a high infiltration of PD-1-positive cells with tumor site PD-L1 expression were more likely to have favorable survival, after adjustment with possible confounders (hazard ratio (HR) = 0.38, p = 0.021, 95% confidence interval (CI) 0.16–0.86). Immunofluorescence staining of CAS samples revealed that PD-L1-positive cells were adjacent to PD-1-positive cells and/or tumor stroma with high IFNγ expression. In vitro stimulation with IFNγ increased PD-L1 expression in two out of three established CAS cell lines. Our results suggest that PD-1/PD-L1 expression is related to CAS progression, and the treatment with anti-PD-1 antibodies could be a new therapeutic option for CAS.